Pharmacotherapy options for membranous nephropathy

Arrigo Schieppati, Giuseppe Remuzzi

Research output: Contribution to journalArticle

Abstract

Introduction: Membranous nephropathy (MN) is a rare, antibody-mediated glomerular disease that causes nephrotic syndrome in adults. It is a chronic disease with spontaneous remissions in approximately 30% of patients. The reminder, however, experience long periods of nephrotic syndrome and progress toward end-stage renal diseases. The ideal treatment for patients with MN is still matter of debate.Areas covered: The PubMed database was searched for original articles and reviews published up to August 2015. The search terms were: membranous nephropathy, prognosis, pathogenesis, and treatment.Expert opinion: Steroids in association with alkylating agents and calcineurin inhibitors are currently used and recommended by international guidelines as treatment of choice in MN. However the treatment benefits are uncertain, and often offset by adverse events. Evidence that B-cell function plays a role in the pathophysiology of this condition has suggested that rituximab, a monoclonal antibody that binds to CD20 antigen on B-cell surface, may be an alternative therapeutic option in MN. Indeed, experience accumulated during the last 10 years has shown that rituximab is effective in inducing remission of proteinuria, with the advantage of a superior safety profile.

Original languageEnglish
Pages (from-to)185-196
Number of pages12
JournalExpert Opinion on Orphan Drugs
Volume4
Issue number2
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Membranous Glomerulonephritis
Drug Therapy
Nephrotic Syndrome
B-Lymphocytes
CD20 Antigens
Spontaneous Remission
Therapeutics
Alkylating Agents
Expert Testimony
Proteinuria
PubMed
Chronic Kidney Failure
Chronic Disease
Steroids
Monoclonal Antibodies
Databases
Guidelines
Safety
Antibodies

Keywords

  • Membranous nephropathy
  • nephrotic syndrome
  • remission
  • rituximab

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Pharmacotherapy options for membranous nephropathy. / Schieppati, Arrigo; Remuzzi, Giuseppe.

In: Expert Opinion on Orphan Drugs, Vol. 4, No. 2, 01.02.2016, p. 185-196.

Research output: Contribution to journalArticle

@article{c60643e34d54465cb7f7f8d9798ec50d,
title = "Pharmacotherapy options for membranous nephropathy",
abstract = "Introduction: Membranous nephropathy (MN) is a rare, antibody-mediated glomerular disease that causes nephrotic syndrome in adults. It is a chronic disease with spontaneous remissions in approximately 30{\%} of patients. The reminder, however, experience long periods of nephrotic syndrome and progress toward end-stage renal diseases. The ideal treatment for patients with MN is still matter of debate.Areas covered: The PubMed database was searched for original articles and reviews published up to August 2015. The search terms were: membranous nephropathy, prognosis, pathogenesis, and treatment.Expert opinion: Steroids in association with alkylating agents and calcineurin inhibitors are currently used and recommended by international guidelines as treatment of choice in MN. However the treatment benefits are uncertain, and often offset by adverse events. Evidence that B-cell function plays a role in the pathophysiology of this condition has suggested that rituximab, a monoclonal antibody that binds to CD20 antigen on B-cell surface, may be an alternative therapeutic option in MN. Indeed, experience accumulated during the last 10 years has shown that rituximab is effective in inducing remission of proteinuria, with the advantage of a superior safety profile.",
keywords = "Membranous nephropathy, nephrotic syndrome, remission, rituximab",
author = "Arrigo Schieppati and Giuseppe Remuzzi",
year = "2016",
month = "2",
day = "1",
doi = "10.1517/21678707.2016.1125779",
language = "English",
volume = "4",
pages = "185--196",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Pharmacotherapy options for membranous nephropathy

AU - Schieppati, Arrigo

AU - Remuzzi, Giuseppe

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Introduction: Membranous nephropathy (MN) is a rare, antibody-mediated glomerular disease that causes nephrotic syndrome in adults. It is a chronic disease with spontaneous remissions in approximately 30% of patients. The reminder, however, experience long periods of nephrotic syndrome and progress toward end-stage renal diseases. The ideal treatment for patients with MN is still matter of debate.Areas covered: The PubMed database was searched for original articles and reviews published up to August 2015. The search terms were: membranous nephropathy, prognosis, pathogenesis, and treatment.Expert opinion: Steroids in association with alkylating agents and calcineurin inhibitors are currently used and recommended by international guidelines as treatment of choice in MN. However the treatment benefits are uncertain, and often offset by adverse events. Evidence that B-cell function plays a role in the pathophysiology of this condition has suggested that rituximab, a monoclonal antibody that binds to CD20 antigen on B-cell surface, may be an alternative therapeutic option in MN. Indeed, experience accumulated during the last 10 years has shown that rituximab is effective in inducing remission of proteinuria, with the advantage of a superior safety profile.

AB - Introduction: Membranous nephropathy (MN) is a rare, antibody-mediated glomerular disease that causes nephrotic syndrome in adults. It is a chronic disease with spontaneous remissions in approximately 30% of patients. The reminder, however, experience long periods of nephrotic syndrome and progress toward end-stage renal diseases. The ideal treatment for patients with MN is still matter of debate.Areas covered: The PubMed database was searched for original articles and reviews published up to August 2015. The search terms were: membranous nephropathy, prognosis, pathogenesis, and treatment.Expert opinion: Steroids in association with alkylating agents and calcineurin inhibitors are currently used and recommended by international guidelines as treatment of choice in MN. However the treatment benefits are uncertain, and often offset by adverse events. Evidence that B-cell function plays a role in the pathophysiology of this condition has suggested that rituximab, a monoclonal antibody that binds to CD20 antigen on B-cell surface, may be an alternative therapeutic option in MN. Indeed, experience accumulated during the last 10 years has shown that rituximab is effective in inducing remission of proteinuria, with the advantage of a superior safety profile.

KW - Membranous nephropathy

KW - nephrotic syndrome

KW - remission

KW - rituximab

UR - http://www.scopus.com/inward/record.url?scp=84958103604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958103604&partnerID=8YFLogxK

U2 - 10.1517/21678707.2016.1125779

DO - 10.1517/21678707.2016.1125779

M3 - Article

AN - SCOPUS:84958103604

VL - 4

SP - 185

EP - 196

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

IS - 2

ER -